KRAS G12C MUTATIONS

Clinical trials for KRAS G12C MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C MUTATIONS trials appear

Sign up with your email to follow new studies for KRAS G12C MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New Triple-Threat attack on Tough-to-Treat colon cancer

Disease control Recruiting now

This study is testing whether a combination of three drugs—adagrasib, cetuximab, and cemiplimab—can help control metastatic colorectal cancer that has a specific genetic change called a KRAS G12C mutation. The trial aims to see how well the treatment works and how safe it is for …

Matched conditions: KRAS G12C MUTATIONS

Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

KRAS G12C MUTATIONS

Get alerted when new KRAS G12C MUTATIONS trials appear

New Triple-Threat attack on Tough-to-Treat colon cancer